GlassScriptPhysician profile
Michael E Hodges
NPI 1679547608
$3,740.72
in general payments reported to CMS, 2019-2025
26 companies · $28.96 in 2025
The $28.96 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $970 · 2021: $723 · 2022: $534 · 2023: $482 · 2024: $161 · 2025: $28.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $671.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $742.75 | 2019-2025 | Repatha, Otezla, Repatha |
| Glaxosmithkline, LLC. | $662.26 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $581.15 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Astellas Pharma US INC | $394.79 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $269.09 | 2019-2022 | |
| Amarin Pharma, INC. | $165.10 | 2020-2021 | |
| Astrazeneca Pharmaceuticals LP | $120.84 | 2019-2024 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $111.15 | 2022-2023 | |
| Abbott Laboratories | $103.72 | 2021-2024 | Freestyle Libre |
| Pfizer INC. | $102.84 | 2020-2025 | |
| Lilly USA, LLC | $56.42 | 2020-2022 | |
| Sunovion Pharmaceuticals INC. | $54.97 | 2020-2022 | |
| Boston Scientific Corporation | $47.66 | 2023 | Wavewriter Alpha Prime 16 |
| Axonics, INC. | $44.27 | 2020-2023 | Axonics |
| E.R. Squibb & Sons, L.L.C. | $41.89 | 2022-2023 | Eliquis |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39.85 | 2021 | |
| Merck Sharp & Dohme LLC | $35.63 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $32.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.20 | 2020-2022 | |
| Eisai INC. | $24.56 | 2020 | |
| Phathom Pharmaceuticals, INC. | $15.77 | 2023 | Voquezna |
| Mylan Specialty L.P. | $15.48 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.96 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.45 | 2021 | |
| Sumitomo Pharma America, INC. | $12.44 | 2023 | Gemtesa |
| Esperion Therapeutics, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.